What changed: Intrahepatic cholangiocarcinoma
Every dated change on the records linked to Intrahepatic cholangiocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval1Trial result7Milestone6This record1
September 2026 · 1
2023 · 2
2022 · 4
- 2022ApprovalFutibatinibFutibatinib approved in US
Previously treated FGFR2-fusion/rearranged intrahepatic cholangiocarcinoma (accelerated)
- 2022Trial resultFOENIX-CCA2FOENIX-CCA2 reported
ORR 42%; PFS 9.
- 2022Trial resultTOPAZ-1TOPAZ-1 reported
OS HR 0.
- 2022MilestoneFOENIX-CCA2FOENIX-CCA2: futibatinib approved; TOPAZ-1: durvalumab added to chemotherapy
A milestone in how this cancer is treated.